539523

- The 52nd Annual General Meeting (AGM) of Alkem Laboratories Ltd. was held on August 27, 2026, through Video Conferencing. - All resolutions set out in the Notice of AGM, including the adoption of financial statements for FY26, confirmation of dividend payment, and re-appointment of directors, were duly approved by the members with requisite majority.

- The 52nd Annual General Meeting (AGM) of Alkem Laboratories Ltd. was held on 27th August, 2026, through Video Conferencing/OAVM. - All resolutions presented at the AGM, including the adoption of audited financial statements for FY ended 31st March, 2026, and the declaration of final dividend, were duly approved by the members with requisite majority. - The re-appointment of Mr. Sandeep Singh and Mr. Sarvesh Singh as directors, and Mrs. Madhurima Singh as an Executive Director for a term of 5 years were also approved. - Additionally, the remuneration for the Cost Auditor for FY ended 31st March, 2026, was ratified.

- HDFC Mutual Fund schemes increased their aggregate holding in Alkem Laboratories Limited to 5.017% of the paid-up equity share capital as of August 24, 2026. This was a 0.021% acquisition via open market, crossing the 5% threshold.

- Q1 FY27 Revenue from operations increased by ~11% YoY to INR3,740 crores, with India sales growing 10.3% and International sales 16%. Net Profit saw a degrowth of 21.7% YoY due to taxation reasons, while EBITDA margin was 20.5% (▲3.7% YoY). - The Daman facility received an OAI status from the U.S. FDA; management anticipates no immediate impact on U.S. supplies and expects resolution within 6-12 months. - Occlutech acquisition was completed mid-July, with an FY27 target of INR400 Cr sales and breakeven EBITDA, slightly off from previous guidance due to integration delays. U.S. CDMO operations incurred a quarterly expense of INR60 Cr, with breakeven expected in 4-5 quarters. - Full-year consolidated tax rate is guided to be 30-32%. The overall India business growth is expected to be ~12% for the year, while the U.S. business is projected for high to mid-single digit growth. - Gross margins are maintained at 66.5% to 67% for the balance of the year.

- Q1 FY27 revenue grew ~11% YoY to INR 3,740 Cr, with India sales up 10.3% and International sales up 16%. - Q1 FY27 Net Profit (PAT) saw a degrowth of 21.7% YoY, mainly due to taxation reasons. - Daman facility received an Official Action Indicated (OAI) status from the US FDA; management expects no current supply disruption and aims for resolution in 6-12 months. - India's full-year business growth guidance (Trade + Branded Formulation) is improved to close to 12%. - US sales outlook for the full year is high single digit to mid, supported by currency; volume growth remains challenging. - US CDMO operations reported INR 60 Cr operational expenses in Q1 FY27, with breakeven targeted in 4-5 quarters at USD 25-30 Mn annual revenue. - Occlutech acquisition FY27 sales target (~INR 400 Cr with breakeven EBITDA) may be slightly delayed due to integration delays. - Denosumab biosimilar approval in the US is delayed by a few months. - Consolidated tax rate for FY27 is projected at 30-32%.

- A meeting of equity shareholders of Alkem Laboratories Limited was held on August 17, 2026, to approve the scheme of amalgamation with Adroit Biomed Limited. - The resolution for the amalgamation was passed with an overwhelming majority, receiving 99.9999% votes in favor.

- Alkem Laboratories Ltd. announced the availability of the audio recording for its Q1FY2027 Earnings Conference Call on the company's website.

- Q1 FY27 Consolidated Revenue ₹3,740.2Cr vs ₹3,371.1Cr (▲10.9% YoY) - EBITDA ₹766.1Cr vs ₹739.1Cr (▲3.7% YoY) - PAT ₹520.0Cr vs ₹664.3Cr (▼21.7% YoY) - EBITDA Margin 20.5% vs 21.9% (▼140bps)

- Q1 FY27 Consolidated Revenue ₹37,402 Mn vs ₹33,711 Mn (▲10.9% YoY) - EBITDA ₹7,661 Mn vs ₹7,391 Mn (▲3.7% YoY) - PAT ₹5,200 Mn vs ₹6,643 Mn (▼21.7% YoY) - EBITDA Margin 20.5% vs 21.9% (▼140bps) - Regulatory Status: Daman (India) facility received Official Action Indicated (OAI) in August 2026 for April 2026 inspection. - Management noted areas for improvement in execution, operational, and regulatory priorities, while investing in R&D, MedTech, and Biotech.

- Intimation regarding the opening of the trading window for Alkem Laboratories Limited. - The trading window, which was closed for the financial results of the quarter ended June 30, 2026, will now open on August 17, 2026. - The financial results for the quarter ended June 30, 2026, were communicated to the Stock Exchanges on August 14, 2026.

- Alkem Laboratories Ltd. to set up a new block within its existing manufacturing facility at Baddi, Himachal Pradesh. - The Board has approved an investment of up to INR 75 crores for this expansion.

- Q1 FY27 Consolidated Revenue ₹37,401.5Mn vs ₹33,711.4Mn (▲11.0% YoY) - EBITDA ₹7,660.5Mn vs ₹7,519.8Mn (▲1.9% YoY) - PAT ₹5,209.8Mn vs ₹6,679.1Mn (▼22.0% YoY) - EBITDA Margin 20.5% vs 22.3% (▼180bps)